Identification of Immune&Driver Molecular Subtypes Optimizes Immunotherapy Strategies for Gastric Cancer
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020696 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Jing Gan und 14 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immunotherapy. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy has become a promising treatment for gastric cancer. However, its effectiveness varies significantly across subtypes because of heterogeneous immune microenvironments and genomic alterations. Here, we established Immune&Driver molecular subtypes CS1 and CS2 by systematically integrating multi-omics data for immune-related and driver genes. CS1 was linked to a better prognosis, while CS2 represented a poorer prognostic phenotype. CS1 displayed enhanced genomic instability, marked by higher mutation frequency and chromosomal alterations. In contrast, CS2 exhibited higher immune activity, with a higher density of immune cell infiltration and increased expression of chemokines and immune checkpoint genes. Among FDA-approved anti-cancer agents included in a pan-cancer drug sensitivity prediction framework, CS1 was predicted to be more sensitive to conventional chemotherapeutic agents, whereas CS2 was predicted to be more responsive to immune-related agents. In melanoma datasets, a CS2-like transcriptomic pattern was associated with improved response to anti-PD-1 therapy, with the combination of anti-PD-1 and anti-CTLA-4 showing more favorable response patterns compared to anti-PD-1 monotherapy. Additionally, we developed an immunotherapy response prediction model using PCA-based logistic regression according to the transcriptional expression of CS biomarkers. The model was trained in melanoma immunotherapy cohorts and validated across independent melanoma datasets, and it further achieved a higher AUC in an external gastric cancer cohort treated with anti-PD-1 therapy. Collectively, this study highlights immune and genomic heterogeneity in gastric cancer and provides a hypothesis-generating framework for exploring immunotherapy response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
ORCID-Profile: Shangwei Ning, Hui Zhi
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gan, J., Yang, B., Wang, S., Zhu, H., Xu, M., Xu, Y., Li, X., Dong, W., Zhao, Y., Liu, M., Feng, W., Liu, Y., Duan, J., Ning, S., & Zhi, H. (2026). Identification of Immune&Driver Molecular Subtypes Optimizes Immunotherapy Strategies for Gastric Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020696
Vancouver
Gan J, Yang B, Wang S, Zhu H, Xu M, Xu Y, et al. Identification of Immune&Driver Molecular Subtypes Optimizes Immunotherapy Strategies for Gastric Cancer. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020696
BibTeX
@article{Gan2026,
author = {Gan, Jing and Yang, Bo and Wang, Shuangshuang and Zhu, Hongbo and Xu, Manyi and Xu, Yongle and Li, Xinrong and Dong, Wenbo and Zhao, Yusen and Liu, Mengmeng and Feng, Wei and Liu, Yujie and Duan, Junjie and Ning, Shangwei and Zhi, Hui},
title = {Identification of Immune&Driver Molecular Subtypes Optimizes Immunotherapy Strategies for Gastric Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020696}
}
EUVIMED